<DOC>
	<DOCNO>NCT01920477</DOCNO>
	<brief_summary>Pemphigus vulgaris ( PV ) rare , chronic , debilitating , potentially life-threatening autoimmune disorder characterize mucocutaneous blister . Ofatumumab novel monoclonal antibody ( mAb ) specifically bind human CD20 antigen , express B lymphocyte . The purpose study evaluate efficacy , tolerability , safety ofatumumab injection subcutaneous use ( ofatumumab SC ) 20 milligram ( mg ) administer every 4 week , ( additional 20 mg load dose [ i.e . 40 mg total ] Week 0 Week 4 ) subject PV . It anticipate sustained B-cell depletion presence ofatumumab SC , resultant reduction pathogenic anti Dsg ( desmoglein ) autoantibodies PV , clinical remission disease result .</brief_summary>
	<brief_title>Efficacy Safety Ofatumumab Treatment Pemphigus Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Pemphigus</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion Adults ( 18 70 year age ) clinicallydocumented diagnosis PV &gt; 2 month &lt; 10 year . History biopsy consistent PV ( Hematoxylin Eosin stain direct immunofluorescence ) . If history , biopsy may perform Screening Period . At least 1 previous episode fail steroid taper ( ie , disease flare/relapse ) prednisone/prednisolone dose &gt; 10 mg/day . The following criterion must meet evidence disease severity time fail steroid taper : ) A Pemphigus Severity Clinical Disease score moderate ( 2 ) severe ( 3 ) ( may historical/retrospective assessment ) . b ) Required treatment change time fail steroid taper least one following : ) A steroid increase &gt; =20 mg/day OR ii ) The addition immunosuppressive/immunomodulatory agent/treatment OR iii ) A dose increase immunosuppressive/immunomodulatory agent/treatment Screening antiDsg antibody consistent diagnosis PV ( ie , elevate antiDsg3 antibody ) . Has initiate receive stable dose prednisone/prednisolone minimum 20 mg/day ( example : 0.25 mg/kg/day 80 kg person ) maximum 120 mg/day 1.5 mg/kg/day ( whichever high ) &gt; =2 week prior randomization . Has exhibit PV disease control , define new lesion &gt; =2 week . A female subject eligible enter study : Is nonchild bear potential , either surgically sterile ( bilateral tubal ligation , bilateral oophorectomy , posthysterectomy ) postmenopausal without menses &gt; 2 year . Women &lt; 2 year postmenopausal require menopausal status confirm folliclestimulating hormone ( FSH ) estradiol level screen evaluation . If FSH estradiol level provide confirmation menopause , subject consider childbearing potential ; Is childbearing potential , defined woman functional ovary , duct , uterus document impairment would cause sterility . This include woman oligomenorrhea ( even severe ) , woman perimenopausal , woman begin menstruate . Subject must negative serum pregnancy test screening must agree consistent correct use acceptable method contraception heterosexual intercourse , begin subject provide informed consent last 12 month last dose investigational product . Acceptable method contraception limit oral contraceptive ( either combine progesterone ) , injectable progesterone , levonorgestrel implant , estrogenic vaginal ring , percutaneous contraceptive patch , intrauterine device intrauterine system documented failure rate &lt; 1 % per year , male partner sterilization ( vasectomy documentation azoospermia ) prior female subject 's entry study ; male must subject 's sole partner , double barrier method ( condom occlusive cap [ diaphragm cervical/vault cap ] vaginal spermicidal agent [ foam/gel/film/cream/suppository ] ) complete abstinence heterosexual intercourse , For Japan subject , list acceptable method contraception , follow method applicable Japan : oral contraceptive progestogen alone , injectable progesterone , levonorgestrel implant , estrogenic vaginal ring , percutaneous contraceptive patch , vaginal spermicidal foam , gel , film , cream French subject : In France , subject eligible inclusion study either affiliate beneficiary social security category . Diagnosis pemphigus foliaceus , paraneoplastic pemphigus , autoimmune blister disease ( pemphigus vulgaris ) . Past current history hypersensitivity component investigational product medically significant adverse effect ( include allergic reaction ) cetirizine ( antihistamine equivalent ) paracetamol/acetaminophen . Prior treatment rituximab without achieve disease control within 6 month initiate rituximab dosing . Prior treatment follow within specify period : time : ofatumumab , total body irradiation , bone marrow transplantation , antiCD4 ; within 2 week : systemic steroid ( except prednisone/prednisolone ) ; within 6 week : live vaccine ; within 8 week : azathioprine , cyclosporine , dapsone , mycophenolate , methotrexate tacrolimus ; within 6 month : cladribine , cyclophosphamide , plasmapheresis , immunoabsorption immunoglobulin therapy , alemtuzumab , mitoxantrone ; within 18 month : Rituximab drug affect number function Bcells Confirmed progressive multifocal leukoencephalopathy ( PML ) , neurological finding potentially consistent PML Evidence history clinically significant infection include : Chronic ongoing active infectious disease require long term systemic treatment , include , limited , chronic renal infection , chronic chest infection bronchiectasis , active hepatitis C ; Positive test hepatitis B surface antigen ( HBsAg ) . For HBsAg negative , hepatitis B core antibody ( antiHBc/HBcAb positive ( regardless hepatitis B surface antibody [ HbsAb ] status ) , HBV deoxyribonucleic acid ( DNA ) test perform subject exclude result positive ; Consult physician experience care management subject hepatitis B manage/treat subject antiHBc positive ; History positive serology human immunodeficiency virus ; Previous serious opportunistic atypical infection ; Prior history , suspicion , tuberculosis ( TB ) ; For Japan : Evidence history clinically significant infection medical condition include : Pneumocystis pneumonia interstitial pneumonia ( base result screen posterioranterior chest Xray , KL6 , betaD glucan ) . Order test local laboratory screen part workup subject sign symptoms potential concern study ; Based Japanese Guideline Hepatitis B , subject HBsAg negative , antiHBc ( HBcAb ) negative , HBsAb positive , HBV DNA test perform subject exclude study result positive ; If follow criterion TB screen meet : Past medical history latent active TB screening ; Sign ( ) symptom ( ) suggestive active TB medical history examination ; Recent close contact patient active TB ; Positive interferongamma release assay tuberculin skin test within 1 month first dose study treatment ; Chest xray , take within 3 month first dose study treatment , show evidence indicate currently active previous TB . For South Korea : Evidence history clinically significant infection include : For subject HBsAg negative , antiHBc ( HBcAb ) negative , HBsAb positive , HBV DNA test perform subject exclude study result positive ; If follow criterion TB screen meet : Past medical history latent active TB screening , Sign ( ) symptom ( ) suggestive active TB medical history examination ; Recent close contact patient active TB ; Positive interferongamma release assay tuberculin skin test within 1 month first dose study treatment ; Chest xray , take within 3 month first dose study treatment , show evidence indicate currently active previous TB . Past current malignancy , except cervical carcinoma Stage 1B less , noninvasive basal cell squamous cell skin carcinoma cancer diagnose duration complete response ( remission ) &gt; 5 year Significant concurrent , uncontrolled medical condition could affect subject 's safety , impair subject 's reliable participation study , impair evaluation endpoint , necessitate use medication allow protocol . This include subject require systemic steroid treatment concurrent medical condition ( pemphigus vulgaris ) . White blood cell ( WBC ) &lt; 3.8 GI/L ( &lt; 3800/mm^3 ) , neutrophils &lt; 2 GI/L ( &lt; 2000/mm^3 ) , platelets &lt; 130 GI/L ( 130,000/mm^3 ) , circulate IgG , IgA , IgM level &lt; 10 % LLN require treatment opinion investigator , alanine aminotransferase ( ALT ) &gt; 2.0 time upper limit normal ( ULN ) , aspartate aminotransferase ( AST ) &gt; 2.0 X ULN , alkaline phosphatase ( ALP ) &gt; 1.5 X ULN , bilirubin &gt; 1.5 X ULN ( except case isolate predominantly indirect hyperbilirubinemia due Gilbert 's syndrome ) . Use investigational drug experimental therapy within 4 week , 5 pharmacokinetic halflives , duration biological effect ( whichever longer ) prior Screening . Electrocardiogram ( ECG ) show clinically significant abnormality show QTc interval ≥450 msec ( ≥480 msec subject bundle branch block ) ( ECG obtain Screening/prior receive first dose study drug ) . Woman breastfeed .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pemphigus</keyword>
	<keyword>( MAB )</keyword>
	<keyword>autoimmune disorder</keyword>
	<keyword>human CD20 antigen</keyword>
	<keyword>subcutaneous</keyword>
	<keyword>Pemphigus vulgaris</keyword>
	<keyword>Phase 3</keyword>
	<keyword>monoclonal antibody</keyword>
	<keyword>ofatumumab</keyword>
	<keyword>PV</keyword>
	<keyword>rare disease</keyword>
</DOC>